Market Signal Briefing

Quick Links:

By

:

Published: Feb 13, 2026, 07:18 GMT+00:00

Gold rebounds to $4,960 after a 3% plunge as CPI at 2.5% looms; silver steadies near $77 while traders watch $5,000 resistance.

Gold and Silver Market Analysis: Recovery Eyes US CPI Data Precious metals are fighting to stay on top after a pretty dramatic “liquidity dump” on February 12 where gold plummeted more than 3% and silver tanked nearly 10%.

Spot Gold is getting back on track at around $4,960-$4,970, sort of clawing its way back from a low of $4,880 earlier. Alright so Thursday was a bit ugly as the liquidation was the result of people having to meet margin calls across asset lines, but gold is bouncing back because – let’s face it, it’s a classic defensive bet.

Silver’s also picking up steam, up around 2.1-2.5% and trading near $76.76-$77.16, because people are on the hunt for bargains after it’s worst one-day shellacking of the year.

US Economic Backdrop and Fed Outlook The US Dollar Index is planted firmly in neutral at 97.05, mainly because of the solid labor market data we got

Jobs: We got a stronger-than-expected 130,000 jobs added earlier this week, which moved the expected Fed rate cut from June all the way to July 2026. Jobless Claims: Initial claims were up at 227,000, which was a tad higher than what the market was expecting but still shows how resilient the labour market is. Inflation Focus: Everyone’s got their eyes on the January CPI print that comes out today – which is gonna be 2.5% if the forecast is to be believed. Global Sentiment: A Flight to Safety Risk sentiment is super fragile right now with global equity indices like the Nikkei 225 and Hang Seng ending the day in the red.

All that red is actually providing a nice tailwind for the gold price though, but people are really hestitant to put their money on the line until they get a sense of what the US inflation print is gonna mean for interest rates.

Gold (XAU/USD) Price Analysis: Descending Trendline Pressures $5,000 Support Gold – Chart Gold is currently trading around $4,956 on the 4-hour chart with it lingering just below the crucial $4,996 resistance that had previously acted as a support – a line in the sand that gold just can’t seem to break through. And for now, price is stuck below a descending trendline that connects the $5,598 swing high, which is putting a limit on short-term momentum despite a few recent comebacks.

The 0.618 Fibonacci retracement of $5,138 keeps acting as a broader hurdle to higher prices, but right now immediate support is coming in at $4,855 with a fall back to $4,682 (0.236 Fibo) a possible option if support does indeed fail.

Now the candlesticks are showing repeated upper wicks near $5,000, which tells us that there’s a decent amount of selling pressure kicking in on any rallies. We also see the 50 period moving average slowly working its way towards $4,990, while the 200-MA is still holding low around $4,780, keeping the medium-term structure pretty intact.

A break above $4,996 would likely trigger a move up towards $5,138 for gold. But, if gold cannot hold above $4,855 then a pullback looks a very distinct possibility.

Trade idea: The idea is to go long above $5,005 and aiming for $5,135 with a stop-loss below $4,880.

Silver (XAG/USD) Price Analysis: Descending Trendline Caps Rebound Near $80 Silver – Chart Silver is sitting right around $76.70 on a 4-hour chart after taking a pretty sharp tumble from the $80.11 resistance point . The price is still stuck below a descending trend line that was drawn from that high of $106.60 , which means that picture overall is looking pretty corrective, even though the price has stabilised a bit recently.

The way the candles have been behaving shows a pretty strong downward momentum trying to get down to $70.37 earlier on in the week , and then a bit of a recovery started forming higher lows. However, the fact that the upper wicks on those candles keep getting knocked back up near $80 shows us that there is still some selling pressure going on. We also got to see the 50-period moving average starting to slope downward at around $84; meanwhile, the 200-day MA is stubbornly stuck right around $86 and that’s just adding to the overhead resistance view.

If the selling starts up again we should see immediate support pop up at $72.00 , and if that happens we are looking at a pretty slide all the way down to $70.37.

Trade idea: If you are looking to get short, you might want to consider doing so below $76.00, targeting a stop around $72.00 but placing your stop above $80.20

Natural Gas and Oil Forecast: Record 3.7M bpd Surplus Sparks Selloff—WTI Below $63, $60 Next?Crude Oil Price Forecast: Testing Key Moving Average SupportGold (XAU/USD) Price Forecast: Pullback Tests Short-Term SupportAbout the Author

Arslan is a finance MBA and also holds an MPhil degree in behavioral finance. An expert in financial analysis and investor psychology, Arslan uses his academic background to bring valuable insights about market sentiment and whether instruments are likely to be overbought or oversold.

Japanese Yen Forecast: USD/JPY Slides as US CPI Report Looms

Dow Jones & Nasdaq 100: Carry Trade Risks Test US Futures Pre CPI Report

Natural Gas Price Forecast: Bullish Signs at Channel Support

Natural Gas and Oil Forecast: Record 3.7M bpd Surplus Sparks Selloff—WTI Below $63, $60 Next?

Crude Oil Price Forecast: Testing Key Moving Average Support

Hydro’s adjusted EBITDA for the fourth quarter of 2025 was NOK 5,587 million, down from NOK 7,701 million in the same quarter last year. The results decreased from lower realized alumina prices and a stronger NOK. This was partly offset by higher primary and alumina volumes and lower raw material costs. Hydro generated NOK 4.6 billion in free cash flow, while the twelve month adjusted RoaCE ended at 10.2 percent.

Alunorte alumina production above nameplate capacity, aluminium smelter production up 2.5 percent year on year Securing power for the Norwegian smelter system with two long-term power contracts and power plant investment Strategic workforce reduction completed and Extrusion Europe restructuring progressing according to plan Proposed dividend of NOK 3.0 per share   "Strong aluminium metal prices continued to provide tailwinds in the fourth quarter, driving near-record earnings in our primary aluminium business and offsetting weak downstream markets. This highlights the robustness of Hydro’s financial position and diversified portfolio,” says Eivind Kallevik, President and CEO of Hydro.  

The fourth quarter saw strong operational performance in the upstream segments. Alumina production at Alunorte exceeded nameplate capacity supported by improved refinery flow and high equipment availability. In Aluminium Metal the ramp up of the previously curtailed capacity at the Norwegian smelters continues and the quarterly production increased by 2.5 percent year on year.

EBITDA for the quarter ended at NOK 5,587 million. Despite seasonally higher investments in the fourth quarter, the free cash flow was NOK 4.6 billion.

The Board of Directors propose to distribute NOK 3.0 per share as cash dividend, representing 60 percent of the 2025 adjusted net income. The proposal yields in total NOK 5.9 billion in shareholder distribution  for 2025 and is subject to approval by the Annual General Meeting on May 7, 2026.

Reliable access to renewable energy remains key to Hydro’s low-carbon aluminium strategy and competitiveness. Hydro signed two long-term power sourcing agreements with Hafslund in the fourth quarter. The agreements cover 5.25 TWh for the period of 2031 to 2040 in price area NO3, which is home to Hydro Sunndal and Hydro Høyanger smelters. Based on renewable energy, Hydro can produce aluminium in Norway with a carbon footprint about 75 percent less than the global average.

In addition to the external power souring, Hydro is investing in its hydropower portfolio. The NOK 1.2 billion Illvatn pumped storage plant project in Norway represents Hydro’s biggest investment in hydropower in more than 20 years. Illvatn will be part of Hydro’s power portfolio supplying renewable energy to aluminium production in Norway.

Hydro announced in November the decision to consolidate the Extrusions operations in Europe with a proposal to close five of its European plants. The closure of the two plants in the United Kingdom is confirmed, and are scheduled to close in late 2026. In the fourth quarter, the five plants were impaired by a total of NOK 398 million, and a provision of NOK 1,226 million was taken for the closure and redundancy cost. Both of these items are excluded from the adjusted EBITDA. An environmental provision of NOK 72 million impacted the adjusted EBITDA in the fourth quarter.

The strategic workforce reduction announced in August 2025 was completed in the fourth quarter. The total number of employees that have left or will leave the company within the first half of 2026 is around 850. The total redundancy cost taken in the third and fourth quarter was NOK 401 million, with no further cost expected in 2026. 

The capital expenditure guidance for the full year was reduced from NOK 15 billion to NOK 13.5 billion in the second quarter. The actual cash effective spend in 2025 ended at NOK 12.1 billion, strengthening the financial flexibility in the face of market unrest and uncertainty.

“Hydro’s relentless focus on operational excellence, cost competitiveness and adaptability has been key to sustaining strong performance in a challenging macro environment. Through dedicated efforts from our 32,000 people we continue to offer attractive shareholder returns, exemplified by the proposed distribution of NOK 3.0 per share for 2025,” says Kallevik.

Results and market development per business area

Adjusted EBITDA for Bauxite & Alumina decreased compared to the fourth quarter of last year, to NOK 1,392 million from NOK 4,969 million, mainly driven by lower alumina sales prices and stronger BRL to USD. This was partly offset by increased sales volumes and positive effects from replacing heavy fuel oil with natural gas in the alumina production. 

PAX traded down to USD 306 per mt at the end of the fourth quarter, from USD 321 at the end of the third quarter, driven by a falling Chinese alumina price and a loosening global alumina balance as alumina production at new refineries in Indonesia continued ramping up. China's alumina market was oversupplied, driving domestic prices down to marginal cash cost of production, however, no significant curtailments have been observed so far. Monthly Chinese bauxite imports from Guinea trended up seasonally in the fourth quarter, driving bauxite prices lower.

Adjusted EBITDA for Energy decreased in the fourth quarter compared to the same period last year, to NOK 1,075 million from NOK 1,151 million. The decrease was mainly due to lower price area gain and no recognition of Markbygden Ett termination compensation this year. This was partly offset by higher production and higher prices.

Average Nordic power prices in the fourth quarter of 2025 increased compared to both the previous quarter and the same quarter last year. The increase from the previous quarter was mainly driven by stronger seasonal demand, below normal wind power production and production outages, while the increase from the same quarter last year was a result of a weaker hydrology. Price area differences between the south and north of the Nordic market narrowed compared to both the previous quarter and the same period last year, in line with weaker hydrology in the northern areas.

Adjusted EBITDA for Aluminium Metal increased in the fourth quarter of 2025 compared to the fourth quarter of 2024, to NOK 3,707 million from NOK 1,949 million, mainly due to higher all-in metal prices and lower alumina cost, partly offset by weaker USD to NOK. Global primary aluminium consumption was higher in the quarter compared to the fourth quarter of 2024, driven by a 1.2 percent increase in world ex. China.​ The three month aluminium price has increased throughout the fourth quarter of 2025, starting at USD 2,688 per mt and ending at USD 2,995 per mt. ​ 

Adjusted EBITDA for Metal Markets decreased in the fourth quarter of 2025 compared to the same period last year, to a negative NOK 56 million from NOK 319 million, due to lower results from sourcing and trading activities, and negative inventory valuation and currency effects, partly offset by increased results from recyclers.

Adjusted EBITDA for Extrusions decreased in the fourth quarter of 2025 compared to the same quarter last year, to a loss of NOK 62 million from NOK 371 million, driven by weaker sales margins in combination with somewhat lower volumes. Increasing U.S. Midwest premium (positive metal effect) compensated for pressured sales margins.

European extrusion demand is estimated to have been flat in the fourth quarter of 2025 compared to the same quarter last year and increasing 3 percent compared to the third quarter. Demand for building & construction and industrial segments have stabilized at historically low levels with some improvements in order bookings. Automotive demand has been negatively impacted by lower European light vehicle production, partly offset by increased production of electric vehicles.

North American extrusion demand is estimated to have been flat in the fourth quarter of 2025 compared to the same quarter last year, but decreasing 8 percent compared to the third quarter, partly driven by seasonality. Extrusion demand has continued to be very weak in the commercial transport segment driven by low trailer builds. Automotive demand has also been weak. Demand has been positive in the building & construction and industrial segments. At the same time, extrusions demand across segments is being subdued due to higher product prices on the back of higher tariffs and duties on aluminium in the U.S.

Other key financials

Compared to the third quarter of 2025, Hydro’s adjusted EBITDA decreased to NOK 5,587 million from NOK 5,996 million, mainly due to lower Extrusion and Recycling margins and volumes as well as increased fixed cost due to seasonality higher maintenance partly offset by higher realized aluminium price and higher upstream sales volumes.

Net income (loss) amounted to negative NOK 2,156 million in the fourth quarter of 2025. Net income (loss) included unrealized derivative losses, mainly on LME related contracts of NOK 2,594 million, rationalization charges and closure costs of NOK 1,493 million, impairment charges of NOK 721 million and transaction related gains of NOK 402 million. The tax effect on these adjustments reflected a standardized tax rate for taxable gains and tax deductible losses. Adjusted net income (loss) for the fourth quarter ended at NOK 1,673 million.

Hydro’s net debt decreased from NOK 13.6 billion to NOK 9.7 billion during the fourth quarter of 2025. The net debt decrease was mainly driven by EBITDA contribution and net operating capital release, partially offset by investments.

Adjusted net debt decreased from NOK 21.1 billion to NOK 18.2 billion, mainly driven by the decrease in net debt of NOK 3.9 billion, partially offset by increased adjustments of NOK 1.0 billion, mainly driven by increased hedging collateral and other liabilities.

Reported earnings before financial items and tax (EBIT), and net income include effects that are disclosed in the quarterly report. Adjustments to EBITDA, EBIT, and net income (loss) are defined and described as part of the alternative performance measures (APM) section in the quarterly report.

Investor contact: 

Baard Erik Haugen

+47 92497191

[email protected]

Elitsa Blessi

+47 91775472

[email protected] 

Media contact: 

Halvor Molland 

+47 92979797

[email protected]

The information was submitted for publication from Hydro Investor Relations and the contact persons set out above. Certain statements included in this announcement contain forward-looking information, including, without limitation, information relating to (a) forecasts, projections and estimates, (b) statements of Hydro management concerning plans, objectives and strategies, such as planned expansions, investments, divestments, curtailments or other projects, (c) targeted production volumes and costs, capacities or rates, start-up costs, cost reductions and profit objectives, (d) various expectations about future developments in Hydro's markets, particularly prices, supply and demand and competition, (e) results of operations, (f) margins, (g) growth rates, (h) risk management, and (i) qualified statements such as "expected", "scheduled", "targeted", "planned", "proposed", "intended" or similar. Although we believe that the expectations reflected in such forward-looking statements are reasonable, these forward-looking statements are based on a number of assumptions and forecasts that, by their nature, involve risk and uncertainty.  

Various factors could cause our actual results to differ materially from those projected in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to: our continued ability to reposition and restructure our upstream and downstream businesses; changes in availability and cost of energy and raw materials; global supply and demand for aluminium and aluminium products; world economic growth, including rates of inflation and industrial production; changes in the relative value of currencies and the value of commodity contracts; trends in Hydro's key markets and competition; and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Except where required by law, Hydro disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

NHY presentation Q4 2025 NHY Fourth Quarter Report 2025

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Charming Medical Limited ("Charming" or "the Company") (NASDAQ: MCTA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 21, 2025, and November 12, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before February 17, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Charming was the subject of an SEC trading suspension in November 2025 after its shares spiked in price dramatically despite no news from the Company justifying its rapid increase. The suspension was based on allegations that the Company's shares were the subject of a promotion scheme involving supposed financial advisors touting the Company on social media and related forums. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Charming, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

SummaryCompaniesNew CEO faces challenge of revamping Sanofi's drug pipelineMust replace star eczema treatment DupixentGarijo becomes Sanofi's first female CEOMixed R&D results and share price drop during Merck KGaA tenureLONDON, Feb 13 (Reuters) - Sanofi's (SASY.PA), opens new tab incoming CEO, 65-year-old Belén Garijo, faces a major task to win over investors, accelerate the French company's stalled drug development pipeline and navigate vaccine scepticism in the United States under President Donald Trump.

Investors, analysts and other people close to Garijo, who has headed Germany's Merck KGaA (MRCG.DE), opens new tab since 2021, told Reuters she was bold, detail-focused and got things done, but also that she had a mixed record on R&D and the share price had dropped during her tenure.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Sanofi's stock, down 25% in the last year, fell 3.5% on Thursday after it said CEO Paul Hudson, 58, whose turnaround drive was stymied by a lack of new blockbuster drugs, would step down this month to be replaced by Garijo in April.

"The CEO change at Sanofi is a sign that R&D transformation has failed or is happening too slowly," said Markus Manns, portfolio manager at Sanofi investor Union Investment. "Belen's priority at Sanofi will be to increase R&D productivity."

Manns lauded Spaniard Garijo's handling of a complex company - Merck has units from health to technology - and a pricing deal sealed with U.S. President Donald Trump last year, but said she needed to step up after several R&D failures at Merck.

"She needs to improve her R&D track record."

REPLACING ASTHMA BLOCKBUSTER DUPIXENT IS A MAJOR CHALLENGEDeveloping new drugs has proved to be Sanofi's biggest issue. Dupixent accounts for over 30% of the company's revenues and it has yet to find a drug to take over once patents begin expiring early in the 2030s, which has weighed on Sanofi's share price.

"Replacing Dupixent is the key strategic challenge for Sanofi," said Nicolas Dumas, a partner at consultancy firm Roland Berger and a Sanofi employee until 2018.

Vaccines, which make up close to a fifth of revenues, are another major issue as sales have dipped in recent years. Hudson had flagged weakness in the segment linked to a more hostile attitude towards vaccines from the U.S. health administration.

Sanofi said Garijo, who worked at the French company for years until 2011, would bring "increased rigour to the implementation of" the company's strategy. Garijo did not immediately respond to requests for comment.

Merck KGaA shares under CEO Belen GarijoSHE WILL BECOME SANOFI'S FIRST FEMALE CEOGarijo will be Sanofi's first female CEO - and the only woman CEO at a large-cap global drugmaker after GSK's (GSK.L), opens new tab Emma Walmsley stepped down this year. She was the first woman to head a German DAX-listed company when she took on the top role at Merck KGaA.

As head of Merck's pharma business, Garijo steered the group's supply chain through the COVID-19 pandemic. She oversaw deals including the group's $3.9 billion purchase of SpringWorks Therapeutics last year.

However, Merck KGaA suffered setbacks in drug development during her tenure and only three new drugs made it to the market.

One investor who worked with Garijo, asking not to be named, said the "visible stuff" - R&D and business development - had not gone well, while adding she had improved the structure of Merck internally and protected the company's margins.

Roel Bulthuis, managing partner at Syncona Limited, a London-based life sciences investment firm, said that Garijo had turned a company "stuck in rules and hierarchy" into a much more bold and effective entity.

"She... challenged executives to have guts to stand up for their decisions and actually get shit done," said Bulthuis, who previously ran M-Ventures, the corporate venture fund of Merck KGaA, during part of Garijo's tenure.

A second investor who worked with Garijo said she was full of energy, dynamic and "on top of things" and also had deep knowledge of Sanofi. "She knows the house, don't underestimate the importance of that," said the person, who also asked not to be named.

CLINICAL BACKGROUND, BUT HOW LONG WILL SHE STAY?A clinical pharmacology specialist, Garijo began her career as a physician at La Paz Hospital in Madrid and is known for her operational execution and attention to detail.

Garijo has "more operations experience than a science background, so will be interesting to see how she can reinvigorate the R&D department in Sanofi," said Claus Henrik Johansen, CEO of Global Health Invest, a Danish healthcare investment fund that holds Sanofi shares.

Some analysts and investors said Garijo had not been on many people's radar, which caught the market slightly by surprise - and they speculated how long she would stay in her new job.

"I think she's a transition CEO. What she's good at, she's someone who can put the organisation under pressure," consultant Dumas said. "She's not there to stay forever."

The line chart shows rebased daily closing prices of Sanofi and some of its European peers in the last five years.Reporting by Bhanvi Satija and Maggie Fick in London, Patricia Weiss and Ludwig Burger in Frankfurt; Editing by Adam Jourdan and Barbara Lewis

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Bhanvi is a London-based reporter covering European pharmaceutical companies and the healthcare industry. She previously covered U.S. health and pharma firms, with a focus on the new weight loss drugs that are transforming the obesity treatment space. Her coverage includes a trend piece on the underuse of their weight-loss drugs among men, increased interest in therapies being developed for preservation of lean mass, and a scoop on gene therapy maker Sarepta defying an FDA order to stop shipping its muscular dystrophy treatment.

Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective. In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year award in the Beat Coverage of the Year category. Since November 2023, she has also been participating in Reuters coverage related to the Israel-Hamas war. Previously based in Nairobi and Cairo for Reuters and in Lagos for the Financial Times, Maggie got her start in journalism in 2010 as a freelancer for The Associated Press in South Sudan.

, /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Kyndryl Holdings, Inc. ("Kyndryl" or "the Company") (NYSE: KD) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Barron's reported on February 9, 2026, that Kyndryl shares "tumbled early Monday after the company said its chief financial officer was leaving amid an accounting review and it reported weaker earnings than expected." Based on this news, shares of Kyndryl fell by more than 55% in morning trading on February 9, 2026.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  uniQure N.V. ("uniQure " or "the Company") (NASDAQ: QURE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  September 24, 2025 to October 31, 2025

DEADLINE: April 13, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. UniQure's Pivotal Study design, including the comparison of the Pivotal Study to the ENROLL-HD data set, did not achieve full FDA approval. The Company understated the chances its BLA application with the FDA would face delays caused by the need for additional studies. Based on these facts, uniQure's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against F5, Inc. ("F5" or "the Company") (NASDAQ: FFIV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 28, 2024 and October 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before February 17, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. F5 touted the strength of its security and ability to fulfill customer needs. In reality, the Company suffered a security incident putting its customers and growth prospects at risk. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about F5, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Varonis Systems, Inc. ("Varonis" or "the Company") (NASDAQ: VRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 4, 2025 and October 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before March 9, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Varonis made extremely optimistic statements about its ability to convert its existing customers to its SaaS offering. The Company knew it was struggling to convince customers to switch to the new platform, reducing the opportunity for ARR growth. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Varonis, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

Q4: 2026-02-12 Earnings SummaryEPS of $0.04 beats by $0.01

 |

Revenue of

$203.08M

(-14.39% Y/Y)

beats by $3.92M

Himax Technologies, Inc. (HIMX) Q4 2025 Earnings Call February 12, 2026 8:00 AM EST

Company Participants

Karen Tiao - Head of IR/PR & Spokesperson
Jordan Wu - Co-Founder, President, CEO & Director

Conference Call Participants

Hsin Yeh - Morgan Stanley, Research Division

Presentation

Operator

Hello, ladies and gentlemen, welcome to Himax Technologies, Inc. Fourth Quarter and Fiscal Year of 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Ms. Karen Tiao, Head of IR/PR in Himax. Ms. Tiao, please go ahead.

Karen Tiao
Head of IR/PR & Spokesperson

Welcome, everyone. My name is Karen Tiao, Head of IR/PR at Himax. Joining me today are Jordan Wu, President and Chief Executive Officer; and Jessica Pan, Chief Financial Officer.

After the company's prepared comments, we have allocated time for questions in the Q&A section. If you have not yet received a copy of today's results release, please e-mail [email protected] or [email protected] or download a copy from Himax's website.

Before we begin the formal remarks, I would like to remind everyone that [Technical Difficulty] conference call, including statements regarding expected future financial results and industry growth, are forward-looking statements that involve a number of risks and uncertainties that could cause actual events or results to differ materially from those described in this conference call.

A list of risk factors can be found in the company's latest SEC filings, Form 20-F in the section entitled Risk Factors as may be amended. Except for the company's full year 2024 financials, which were provided in the company's 20-F and filed with SEC on April 2, 2025, the financial information included in this conference call is unaudited and consolidated and prepared in accordance with IFRS accounting.

Such financial information is

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia® (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p = 0.057) at Week 136, 4 weeks after the end of study treatment1.

Clinically meaningful results were observed with Vanrafia compared to placebo in eGFR change from baseline at the end of study treatment at Week 132, and in the prespecified exploratory group of patients additionally receiving sodium-glucose co-transporter-2 (SGLT2) inhibitors1. At the end of treatment at Week 132, the eGFR change from baseline compared to placebo was 2.59 ml/min/1.73 m2 (nominal 2- sided p = 0.039)1.

“Progressive and complex diseases such as IgAN present an urgent need for medicines that can target the different drivers of the disease. Vanrafia can be seamlessly integrated into patients’ existing treatment plans, with a consistent safety profile,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal & Metabolic Development Unit, Novartis. “We are pleased with today’s Phase III ALIGN results, which add to the growing evidence of Vanrafia as a potential foundational therapy to slow kidney function decline.”

ALIGN provides the longest follow-up period in pivotal Phase III studies for IgAN3. Safety was consistent with previous findings1.

Alongside Vanrafia, Novartis continues to advance its multi-asset IgAN portfolio, which also includes Fabhalta® (iptacopan) and investigational compound zigakibart.

About IgAN
IgAN is a progressive autoimmune kidney disease with approximately 25 per million people newly diagnosed worldwide each year4. IgAN is highly debilitating as it leads to glomerular inflammation (when the small filters in the kidneys are inflamed), proteinuria (excess protein in urine), and a gradual decline in eGFR5. Up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis or kidney transplantation as part of long-term disease management5-7.

Furthermore, people living with IgAN often face mental, social, and economic challenges5-8. Supportive care has not addressed the underlying causes of the disease and often fails to slow disease progression, reinforcing the need for more targeted therapies for IgAN4-9.

About Vanrafia® (atrasentan)
Vanrafia (atrasentan) is a potent and highly selective endothelin A (ETA) receptor antagonist, which is part of the endothelin system, a key system involved in the progression of IgAN10-13.

Vanrafia is the first and only selective ETA receptor antagonist approved for primary IgAN, a once-daily, oral treatment and can be seamlessly added to, or used alongside, existing supportive care (e.g. renin-angiotensin system (RAS) inhibitor with or without SGLT2 inhibitor) without the need for titration2. Vanrafia does not require a Risk Evaluation and Mitigation Strategy (REMS) program. Because some endothelin receptor antagonists have caused elevations of aminotransferases, hepatotoxicity, and liver failure, clinicians should obtain liver enzyme testing before initiating Vanrafia and during treatment when clinically indicated. Vanrafia may cause serious birth defects2.

About ALIGN
The ALIGN study (NCT04573478) is a global, randomized, multicenter, double-blind, placebo-controlled Phase III clinical trial comparing the efficacy and safety of Vanrafia versus placebo in patients with IgAN at risk of progressive loss of kidney function1-3. In total, 340 patients with biopsy-proven IgAN with baseline total proteinuria ≥1 g/day despite optimized RAS inhibitor treatment were randomized to receive once-daily, oral Vanrafia (0.75 mg) or placebo for approximately 132 weeks1,11. Patients continue receiving a maximally tolerated and stable dose of a RAS inhibitor as supportive care1,11. An additional cohort of 64 patients receiving an SGLT2 inhibitor in addition to RAS inhibitor for at least 12 weeks was also enrolled1,11. The primary efficacy endpoint for the interim analysis (in 270 patients) was change in proteinuria, as measured by 24-hour urine protein-to-creatinine ratio (UPCR) from baseline to 36 weeks1,3,11. The key secondary endpoint for the final analysis is the change from baseline to 136 weeks in kidney function as measured by eGFR. Other secondary efficacy endpoints as well as safety and tolerability are also assessed1-3.

Novartis commitment to kidney diseases 
Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need.

Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms - whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis, and get patients the right care, sooner.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

, /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  April 1, 2024 to December 16, 2025
DEADLINE: March 16, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Vistagen misled investors about the results of its PALISADE-2 trial of fasedienol. The Company created the false impression that its drug candidate would enjoy a successful Phase 3 trial. Based on these facts, Vistagen's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
 Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Ardent Health, Inc. ("Ardent " or "the Company") (NYSE: ARDT ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of ARDT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  July 18, 2024 to November 12, 2025

DEADLINE: March 9, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Ardent utilized a 180-day cliff on accounts receivable so it could report higher amounts of accounts receivable and delay recognizing losses. Based on these facts, Ardent's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against BellRing Brands, Inc. ("BellRing" or "the Company") (NYSE: BRBR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of BRBR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  November 19, 2024 to August 4, 2025
DEADLINE: March 23, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. BellRing misled the market by claiming it enjoyed strong customer demand and a strong competitive position in the market. In fact, its sales were driven by customers stockpiling inventory. Based on these facts, BellRing's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
 Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Beyond Meat, Inc. ("Beyond Meat" or "the Company") (NASDAQ: BYND) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 27, 2025 and November 11, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before March 24, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Beyond Meat carried a higher book value for long-lived assets than their fair value. The Company was likely to be required to record a non-cash impairment charge due to this issue. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Beyond Meat, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

A great quarter wasn't enough to save Monday.com from a 25% plunge. The real culprit might surprise you.

Shares of Monday.com (MNDY +0.74%) plunged this week, according to data from S&P Global Market Intelligence. From last Friday's market close to the closing bell on Feb. 12, the stock price fell 25%.

True to its name, Monday.com reported earnings early Monday morning. The report itself was better than expected, but the company disappointed investors with modest guidance for the next fiscal year.

Today's Change

(

0.74

%) $

0.54

Current Price

$

73.63

Great quarter, scary guidance withdrawal Let's start with the basic financials. Monday.com's revenue rose 25% year over year, landing at $333.9 million. Adjusted earnings fell from $1.08 to $1.04 per diluted share. In both cases, Wall Street expected something worse. The analyst consensus pointed to earnings near $0.92 per share on revenue in the neighborhood of $329.5 million.

The results also exceeded the midpoints of Monday.com's guidance ranges, which aimed at revenue around $329 million and significantly weaker operating income.

However, management withdrew its existing 2027 guidance due to currency exchange headwinds and "the evolving nature of the AI landscape," according to conference call comments. Many investors saw this canceled guidance as a sign that AI agents are stealing Monday.com's business in the project management and online collaboration markets. The stock closed 20.1% lower that day and hovered around that lower level for the rest of the week.

Image source: Getty Images.

Is Monday.com sandbagging again? This company has a history of setting modest guidance targets and hitting them out of the park with stronger real-world performance. Revoking longer-term growth goals would take the lowballing to a new level, but management projects roughly 18% revenue growth and 28% higher adjusted operating profits in 2026. Those are lofty growth targets.

And Monday.com is taking action against the potential AI challenge. The company offers its own AI agent platform, letting clients integrate multi-step AI tools in their Work OS applications. In the end, AI could be more of an opportunity than a threat for this innovative company.

I think the resulting price drop was an overreaction. If you don't own any Monday.com stock yet, this could be a good time to get started.

Anders Bylund has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Monday.com. The Motley Fool has a disclosure policy.

SummaryCompaniesGE Aerospace targets more repairs via automation in SingaporeRobots learn blade-work once done by handBacklogs may ease, but shortages persistSINGAPORE, Feb 13 (Reuters) - GE Aerospace (GE.N), opens new tab technician Suresh Sinnaiyan has spent more than a decade repairing jet‑engine compressor blades by guiding them across a sanding belt with practised precision.

Now, at the aerospace giant's new automation lab in Singapore, he is teaching a robot to do the same job.

Stay up to date with the latest news, trends and innovations that are driving the global automotive industry with the Reuters Auto File newsletter. Sign up here.

The switch is part of GE's push to prepare the next wave of industrial development and ease one of aviation's biggest bottlenecks: overloaded repair shops and scarce parts.

Unexpected wear and tear in the latest generation of jet engines across the industry has idled many jets and led airlines to keep older jets flying longer, stretching maintenance lines into months as engines wait their turn in repair queues.

That pressure has turned into a public fight. Airlines have complained that engine makers are benefiting from shortages by raising prices, while manufacturers say they are pouring money into expanding support after shouldering huge development costs.

Tony Fernandes, the co-founder of Malaysian low-cost airline AirAsia, put it candidly: "They have got to remember airlines are their future and treat us as partners," he told Reuters, referring to the industry overall.

SINGAPORE AS THE PRESSURE VALVEGE says Singapore is a key piece of its answer.

The company's 2,000-employee repair hub is being upgraded with more automation, digital tools and AI as part of a plan that GE has said could total up to $300 million in investment.

The company aims to lift repair volume in Singapore by 33% without expanding the site's footprint — by reorganising work, reshaping floor space and automating tasks where it is efficient.

The plant is at the forefront of efforts to roll out "Flight Deck," GE's version of the "Lean" manufacturing recipe of continuous improvement and eliminating waste pioneered by Japanese carmakers and championed by CEO Larry Culp.

"It's not about sprinting at quarter's end to make a Wall Street guide. It is making every hour and every day count," Culp told Reuters in an interview.

GE and rivals such as Pratt & Whitney (RTX.N), opens new tab have been trying to balance feeding new-airplane assembly lines with engines and parts while keeping the existing fleet flying.

Repairing more used parts can ease pressure by safely reducing the need to replace worn components with newly manufactured ones — leaving more available for new engines.

And GE says repairs can halve the time needed for key processes as well as halve the cost to airlines.

FASTER TURNS, TIGHTER FLOOR SPACE"Repair can really improve turnaround time … the less time the engine is off the wing, the better," Iain Rodger, head of GE Aerospace Component Repair Singapore, told Reuters during a visit to the facility.

One example is a reorganised repair area overhauling used and scorched CFM56 turbine nozzles — parts that endure extreme heat inside one of the world's most widely used engines.

Workers say turnaround time there has improved since 2021, when it was 40 days, and GE is targeting 21 days by 2028.

The area is giving up roughly a third of its floor space to prepare for the next challenge: developing repair capability for newer LEAP engines that are beginning to enter overhaul cycles.

Without approved repairs, airlines may need to replace worn parts with new ones, which are typically more expensive and in limited supply.

"Now we can see problems and identify where issues are," said Nozzles Business Leader Han Hui Min of the new layout.

TEACHING ROBOTS THE HUMAN TOUCHThe most compelling work is also among the hardest to automate: repairs that depend on a technician's touch.

Take those compressor blades from a CFM56 engine.

As air rushes into the core of the engine, spinning blades squeeze it to build pressure. Over years of use, blade tips deform and must be restored in a process called blending — reshaping the metal so it meets tight tolerances.

"It's really hard to do. (Until now) it is 100% manual," said Sinnaiyan. Each blade has to be filed to within a few thousandths of an inch, relying on eye, feel and coordination.

GE's bet is that if it can capture that skill in a repeatable robotic process, it can reduce dependence on scarce specialised labour and increase throughput at lower cost.

Analysts note that engine makers earn some of their biggest profits from servicing used parts and from licensing certain repairs to other shops in return for lucrative royalties.

That means the process for each repair is considered the secret sauce for an increasingly crucial part of the business.

Even so, scaling repairs has limits. Work must follow approved procedures and strict quality controls.

And a slowdown in new plane production which boosted the demand for old jets - and in turn demand for repairs - is coming towards an end, Agency Partners analyst Nick Cunningham said.

If GE's changes in Singapore deliver, they could help the industry work through its bottlenecks and ease fares.

But airline executives and others have cautioned that the underlying supply squeeze is unlikely to vanish quickly.

"It is about moving away from fire fighting and heroics to a different type of preferred performance," Culp said.

Reporting by Tim Hepher in Singapore and Rajesh Kumar Singh in Chicago; Editing by Joe Brock and Matthew Lewis

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Rajesh Kumar Singh is the U.S. Aviation Correspondent at Reuters, based in Chicago, where he reports on airlines, aircraft manufacturers, and regulatory developments that shape the global aviation industry. Prior to this role, he covered U.S. manufacturing and trade policy, including the U.S.–China trade wars, where his work delved into the disruption facing American businesses and the strategic responses of major corporations. He began his career with Reuters in India, where he reported on a wide range of issues covering the country's economic complexities—from its recovery after the global financial crisis to the challenges of inflation and governance.

Roku, Inc. (ROKU) Q4 2025 Earnings Call Transcript

Summary: For Meta (META) and Microsoft (MSFT), it has indeed been a tale of two tech giants as of late.

Shares in Norwegian Cruise Line have underperformed its peer set significantly over the past year. The discount in valuation to both its peers and to the broader market indexes presents an attractive buying opportunity, in my view. I see the company benefitting from a strong wave season through 2026 and beyond.

Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call February 12, 2026 4:30 PM EST

Company Participants

Joseph Sardano - Co-Founder, Chairman & CEO
Michael Sardano - President, Chief Commercial Officer, General Counsel, Corporate Secretary & Director
Javier Rampolla - Chief Financial Officer

Conference Call Participants

Tirth Patel - Lippert/Heilshorn & Associates, Inc.
Anthony Vendetti - Maxim Group LLC, Research Division
Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division

Presentation

Operator

Good afternoon, and welcome to the Sensus Healthcare Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Tirth Patel with Alliance Advisors IR. Please go ahead.

Tirth Patel
Lippert/Heilshorn & Associates, Inc.

Good afternoon. This is Tirth Patel with Alliance Advisors IR. Thank you all for joining today's call to discuss Sensus Healthcare's Fourth Quarter and Full year 2025 financial results.

Joining me from Sensus are Joe Sardano, Chairman and Chief Executive Officer; Michael Sardano, President, Chief Commercial Officer and General Counsel; and Javier Rampolla, Chief Financial Officer.

As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends or anticipates and other similar expressions will, should or may occur in the future are forward-looking statements.

The forward-looking statements are management's beliefs based upon currently available information as of the date of this conference call, February 12, 2026. Sensus Healthcare undertakes no obligation to revise or update any forward-looking statements, except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K, 10-Q and other SEC filings.

During today's call, references will be

One of Wall Street's darlings of the last few years is getting hammered.

Let's just cut to the chase. Palantir (PLTR 4.83%) stock still looks overvalued, and I'm still not buying.

But why? After all, the artificial intelligence data and analytics platform company reported extraordinary fourth-quarter results, featuring a 70% year-over-year increase in revenue. Even more, the midpoint of the company's guidance implies even faster revenue growth in the first quarter of 2026. And what is Palantir management saying? The company is "in the middle of a tectonic shift" in the adoption of its software.

So, why wouldn't I like a stock like this?

The problem boils down to valuation. The stock is simply priced for perfection, leaving essentially no room for error -- and not even enough room for a natural deceleration in the company's growth over the next 5 years.

Image source: Getty Images.

Before we dive into more details, let me make one more thing clear: saying the stock is not attractive is not a critique of the management team or the business itself. This is a great business, and the company is executing exceptionally well. But sometimes when companies are at the center of the market's most exciting investment theme, the best-performing companies can see their stocks soar a bit too far. This is what happened to Palantir. Even after the growth stock's recent pullback, shares are up more than 1,600% over the past three years.

Accelerating growth Palantir's revenue isn't just growing fast; it's accelerating. The year-over-year revenue growth rates for Palantir in the first, second, third, and fourth quarters of 2025 were 39%, 48%, 63%, and 70%, respectively. With a top-line trend like this, it's easy to see why investors love this business.

Making the company's recent performance even more impressive, Palantir's profitability has inflected recently. Palantir's net income in 2025, for instance, rose more than 250% year over year to $1.625 billion.

But what if growth slows? The problem, however, is that the stock's price-to-earnings ratio of more than 200 as of this writing prices in more strong growth like this for years to come.

To provide more perspective on the stock's valuation, consider its market capitalization. As of this writing, Palantir commands a market capitalization of more than $306 billion despite trailing-12-month sales and net income of approximately $4.5 billion and $1.6 billion, respectively. The gap between Palantir's market capitalization and its underlying fundamentals is a chasm.

Today's Change

(

-4.83

%) $

-6.55

Current Price

$

129.13

Even when you take the stock's price as a multiple of analysts' consensus earnings-per-share forecast over the next 12 months, shares are expensive. The stock's forward price-to-earnings ratio is about 110 as of this writing.

A valuation like this could be a disaster waiting to happen if the company's growth starts to slow. And while Palantir's first-quarter guidance suggests a slowdown won't occur anytime soon, it could be on the horizon. Just look at Palantir's decelerating growth rate in its total contract value (TCV), or the potential lifetime value of its customer contracts. The company closed $4.3 billion worth of TCV in Q4. This was up 138% year over year -- a slowdown from 151% growth in Q3.

Of course, it's not like this 138% growth in closed TCV during Q4 is poor performance. Management should be extremely proud of this performance. But if closed TCV continues to decelerate throughout 2026, it could signal slower revenue growth.

Overall, Palantir's business continues to fire on all cylinders. But there's a price for everything, and the price for Palantir stock arguably remains egregious. While it's always possible that Palantir delivers the extraordinary growth required to justify its valuation and still reward shareholders with attractive returns from here, I don't think the risk is worth it at the stock's current price.

The Magnum Ice Cream Company N.V. (MICC) Q4 2025 Earnings Call February 12, 2026 5:00 AM EST

Company Participants

Michele Negen
Peter Kulve - CEO & Executive Director
Abhijit Bhattacharya - CFO & Executive Director

Conference Call Participants

Warren Ackerman - Barclays Bank PLC, Research Division
Celine Pannuti - JPMorgan Chase & Co, Research Division
Jeff Stent - BNP Paribas, Research Division
David Roux - Morgan Stanley, Research Division
Karel Zoete - Kepler Cheuvreux, Research Division
Robert Jan Vos - ODDO BHF Corporate & Markets, Research Division
Bingqing Zhu - Rothschild & Co Redburn, Research Division
David Hayes - Jefferies LLC, Research Division
Antoine Prevot - BofA Securities, Research Division
Jeremy Kincaid - Kempen & Co. N.V., Research Division
Guillaume Gerard Delmas - UBS Investment Bank, Research Division

Presentation

Operator

Good morning, and welcome to The Magnum Ice Cream Company Webcast for the Full Year 2025 Results. My name is Heidi, and I will be your operator for today's call.

Before we begin, please note that today's presentation is being recorded. [Operator Instructions]

With that, I am pleased to turn the call over to Michele Negen. Michele, please go ahead.

Michele Negen

Good morning, everyone. Welcome to The Magnum Ice Cream Company's First Full Year 2025 Results Webcast. My name is Michele Negen, Head of Investor Relations, and I'm here today with our CEO, Peter ter Kulve; and our CFO, Abhijit Bhattacharya.

The press release and investor presentation were published on our Investor Relations website this morning. The replay and full transcript of this webcast will be made available after the call as well.

Before we start, I want to draw your attention to our cautionary statement on the screen. You will also find this statement in the presentation published on the website.

In a moment, Peter will talk you through the key elements of our performance in 2025 and

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Phoenix Education Partners, Inc. (NYSE: PXED) resulting from allegations that Phoenix Education may have issued materially misleading business information to the investing public.

So What: If you purchased Phoenix Education securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=50770 mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On January 3, 2026, Fox News published an article entitled "University of Phoenix data breach hits 3.5M people." The story stated that the "University of Phoenix has confirmed a major data breach affecting nearly 3.5 million people. The incident traces back to August when attackers accessed the university's network and quietly stole sensitive information."

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P.A.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BATRA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryCompaniesDeutsche Bank Private Bank taps more bankers for emerging markets franchiseClients seeking diversification, opening more accounts in EuropeBank aims to capitalise on rising interest in Lombard loansSINGAPORE, Feb 13 (Reuters) - Deutsche Bank (DBKGn.DE), opens new tab plans to add up to 50 relationship managers in its emerging markets private banking unit this year, said a senior executive, as the European lender seeks to bolster its wealth footprint in the Gulf region and North Asia.

Marco Pagliara, head of emerging markets at Deutsche Bank Private Bank, told Reuters that "selective hiring" would also continue in 2027 and 2028, without giving specific targets or disclosing the number of relationship managers it has by region.

The Week in Breakingviews newsletter offers insights and ideas from Reuters' global financial commentary team. Sign up here.

The hiring spree is part of the private bank's aim to grow its emerging markets front office headcount by 50% over the next three years. A large number of the 250 bankers it aims to hire under a previously announced plan are set to be in the franchise.

CAPTURING GROWING GLOBAL WEALTHThe move comes as global banks have been ramping up their private banking offerings in recent years, especially in the fast-growing regions of Asia and the Middle East, to tap into the expanding population of millionaires and billionaires.

Global financial wealth reached an all-time high of $305 trillion in 2024, according to Boston Consulting Group's Global Wealth Report 2025.

Diversification, including where investors hold assets and how they allocate capital, has been a growing theme among the bank's wealthy clients, Pagliara said, amid rising global market volatility.

For instance, clients who previously held assets in Singapore or Hong Kong are now more likely to use other wealth centres as well, like Switzerland, Luxembourg and the UK, he said, as allocations to Europe-domiciled investments increase.

Switzerland will be another focus of the private bank's headcount expansion, Pagliara added.

The trend is in line with a push from money managers to invest in a broader range of asset classes across markets, particularly away from the United States, as geopolitical ructions and unpredictable policymaking weigh on sentiment.

"This diversification not only reflects (ultra-high-net-worth) family aspirations for global assets like real estate, it also reflects the clients' desire to diversify assets geographically to mitigate geopolitical risk," Pagliara said.

GROWING APPETITE FOR LEVERAGELombard lending - where private banking clients borrow against the value of their investment portfolios - is another area where the private bank is aiming to double down amid growing interest.

"Right now, I'm seeing more clients using the dry powder they've got," Frankfurt-headquartered Deutsche Bank Private Bank's global head of wealth management and business lending, Adam Russ, said in a separate interview.

"It's not a case of clients aggressively leveraging, but they are just taking leverage up a tick."

According to a 2024 report by Deloitte, Lombard lending, which helps private banks expand their assets under management, has been one of the fastest growing credit products since 2018, with a global market size of around $4.3 trillion.

"There's a lot of pent-up supply that can be used if people feel real conviction around certain trades, which is good, you know, being in a market like we're in right now," said Russ.

"Lombard lending is becoming more and more of a focus for us."

Reporting by Rae Wee; Editing by Sumeet Chatterjee and Kevin Buckland

Our Standards: The Thomson Reuters Trust Principles., opens new tab